Tags

Type your tag names separated by a space and hit enter

[Current use of bisphosphonates in clinical oncology].
Lijec Vjesn. 1999 Sep-Oct; 121(9-10):296-301.LV

Abstract

Bisphosphonates represent nowadays a standard therapy of tumor induced hypercalcemia and are progressively more used in the treatment of tumor bone metastatic disease. Among several bisphosphonates, pamidronate is one of the most commonly used in clinical practice, so we also used it in succesful treatment of patients with breast cancer bone metastases. It has been shown that pamidronate reduces the frequency of hypercalcemia, bone pain and pathological fractures, although the mechanisms by which these effects are achieved are not completely clarified. Bisphosphonates are also important not only in treating patients with present metastases but also in prevention, or at least, delay of bone metastases onset. Recently, there are clinical trials examining the so called adjuvant therapy, that means the use of bisphosphonates in prevention of bone metastases in high risk breast cancer patients without distant metastases. In addition to breast cancer, multiple myeloma is another area of successful bisphosphonate application. In this paper we present some of the clinical results following the use of pamidronate in breast cancer- and hypernephroma-patients with hypercalcemia.

Authors+Show Affiliations

Klinika za patofiziologiju Medicinskog fakulteta, KBC Zagreb.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

hrv

PubMed ID

19658372

Citation

Vrbanec, D, et al. "[Current Use of Bisphosphonates in Clinical Oncology]." Lijecnicki Vjesnik, vol. 121, no. 9-10, 1999, pp. 296-301.
Vrbanec D, Plestina S, Belev B, et al. [Current use of bisphosphonates in clinical oncology]. Lijec Vjesn. 1999;121(9-10):296-301.
Vrbanec, D., Plestina, S., Belev, B., Unusić, J., & Pavlinić-Diminić, V. (1999). [Current use of bisphosphonates in clinical oncology]. Lijecnicki Vjesnik, 121(9-10), 296-301.
Vrbanec D, et al. [Current Use of Bisphosphonates in Clinical Oncology]. Lijec Vjesn. 1999 Sep-Oct;121(9-10):296-301. PubMed PMID: 19658372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Current use of bisphosphonates in clinical oncology]. AU - Vrbanec,D, AU - Plestina,S, AU - Belev,B, AU - Unusić,J, AU - Pavlinić-Diminić,V, PY - 2009/8/8/entrez PY - 1999/9/1/pubmed PY - 2009/9/3/medline SP - 296 EP - 301 JF - Lijecnicki vjesnik JO - Lijec Vjesn VL - 121 IS - 9-10 N2 - Bisphosphonates represent nowadays a standard therapy of tumor induced hypercalcemia and are progressively more used in the treatment of tumor bone metastatic disease. Among several bisphosphonates, pamidronate is one of the most commonly used in clinical practice, so we also used it in succesful treatment of patients with breast cancer bone metastases. It has been shown that pamidronate reduces the frequency of hypercalcemia, bone pain and pathological fractures, although the mechanisms by which these effects are achieved are not completely clarified. Bisphosphonates are also important not only in treating patients with present metastases but also in prevention, or at least, delay of bone metastases onset. Recently, there are clinical trials examining the so called adjuvant therapy, that means the use of bisphosphonates in prevention of bone metastases in high risk breast cancer patients without distant metastases. In addition to breast cancer, multiple myeloma is another area of successful bisphosphonate application. In this paper we present some of the clinical results following the use of pamidronate in breast cancer- and hypernephroma-patients with hypercalcemia. SN - 0024-3477 UR - https://www.unboundmedicine.com/medline/citation/19658372/[Current_use_of_bisphosphonates_in_clinical_oncology]_ DB - PRIME DP - Unbound Medicine ER -